SATELLOS BIOSCIENCE INC. TO PRESENT GAME CHANGING SCIENCE AT INSIGHTS IN RESEARCH INVESTOR SUMMIT AND MDA CLINICAL & SCIENTIFIC CONFERENCE 2022
- Ryan Mitchell, PhD and Director of Business Development to highlight new advancements with Satellos’ novel muscle regeneration technology
TORONTO, ONTARIO, MARCH 10, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos has been selected to present at the upcoming Insights in Research Investor Summit and MDA Clinical and Scientific Conference Nashville, Tennessee, March 13-16, 2022. Dr. Ryan Mitchell, Director of Business Development, will make presentations that focus on what Satellos believes to be game changing advancements that the company’s researchers are making in the science behind skeletal muscle regeneration.
March 13, 2022: 9:10 am – 9:30 am CT (Investor Summit)
March 15, 2022: 10:30 am – 10:50 am CT (Clinical Conference)
Title: Rebuilding muscle from within
March 13-15, 2022: 6:00 pm – 8:00 pm CT
Title: Rebuilding muscle in Duchenne by correcting stem cell polarity
“We are excited to share the latest advancements in our efforts to drastically improve the quality of life of individuals with Duchenne, and the unique and proprietary science designed to correct deficits in stem cell polarity that our research has shown are drivers of the progressive muscle destruction of this tragic disease,” said Frank Gleeson, Satellos Co-Founder and CEO. “By restoring stem cell polarity and production of muscle progenitor cells via our novel small molecule treatment approach we believe it is possible to restore regeneration thereby modifying disease course and improving outcomes for patients with Duchenne and a range of other dystrophies.”
In his presentation Dr. Mitchell will present findings that show muscle stem cells in Duchenne are unable to both adequately repair existing and generate new muscle fibers throughout life, which implies that the progressive muscle destruction experienced by people living with Duchenne is actually caused by a failure of the body’s natural regeneration process. The presentation will delve into ways the company has identified to restore muscle regeneration with small molecule drugs that regulate stem cell “polarity” and enable production of the muscle progenitor cells on which repair and regeneration depends. Satellos believes that restoring regeneration has the potential to be disease modifying in Duchenne and other dystrophies and offers a new treatment approach to improve the lives of patients. Once available, posters and presentations will be on the Company website at https://satellos.com.
Satellos expects to advance drug candidates and file IP in the first half of 2022, selecting multiple candidates suitable for Proof of Concept (PoC) testing and optimization. The company expects to initiate Pre-IND studies before the end of 2022 and initiate First-in-Human clinical studies during 2023.
About Satellos Bioscience Inc.
Satellos is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has shown how defects in a process known as stem cell “polarity”, which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the continuous and accumulating damage their muscles experience. Satellos’ lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. For more information about or to discuss potential collaborations with Satellos concerning our discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, PhD, Director – Business Development at [email protected] or visit Satellos.com.
For more information about Satellos please contact:
Notice on forward-looking statements:
This press release includes forward-looking information or forward-looking statements within the meaning of Canadian and U.S. securities laws regarding Satellos and its business, which may include, but are not limited to, statements with respect to the anticipated benefits of modulating stem cell polarity; its prospective impact on Duchenne patients and muscle regeneration generally; projected benefits of Satellos’ therapeutic approach, including small molecule drug candidates; Satellos’ technologies and drug development plans; the timeline to commence clinical trial testing in humans; the planned advancement of Satellos research and development; and the Company’s priorities and anticipated achievement of milestones and evaluation plans for drug molecules. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “progress”, “aim”, “plan”, “expect”, “intend”, “anticipate”, “estimate”, “believe”, “objective”, “potentially”, “possibly”, “ongoing efforts”, “develop”, “pioneering”, “milestone”, “further”, “prospect” , “game changing” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks relating to the pharmaceutical and bioscience industry, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally. Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Not for US distribution
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.